Bronchogenic carcinoma
Therapeutic area
Oncology
Rare disease
No
- Definition
- A lung carcinoma arising from the bronchial epithelium.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Bronchogenic carcinoma
- Therapeutic area
- Oncology
- bronchogenic carcinoma
- bronchial carcinoma
- bronchiogenic carcinoma
- bronchogenic carcinoma
- bronchogenic lung cancer
- bronchogenic lung carcinoma
- bronchus carcinoma
- carcinoma of bronchus
- carcinoma, bronchial, malignant
- Severity
- Severe
- Oncology
- Pulmonology
- MONDO ID
- MONDO:0002806
- Parent condition
- MONDO:0001672
Related records
Broader conditions (23)
- Bronchial disorder
- Bronchial neoplasm
- Bronchus cancer
- Cancer
- Cancer or benign tumor
- Carcinoma
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Epithelial neoplasm
- Human disease
- Lower respiratory tract disorder
- Lung cancer
- Lung carcinoma
- Lung disorder
- Lung neoplasm
- Neoplasm
- Neoplasm of thorax
- Neoplastic disease or syndrome
- Respiratory system cancer
Narrower conditions (2)
- Bronchus carcinoma in situ
- Bronchus mucoepidermoid carcinoma
Trials (65)
- (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
- (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
- (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
- A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors
- A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
- A New Pathway With BronchOscopic or Oesophageal Ultrasound for Lung Cancer Diagnosis and STaging (BOOST)
- A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC
- A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection
- A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)
- A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
- A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
- A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
- A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC
- A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC
- A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy
- A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)
- A Vaccine Trial for Patients With Stage IIIB, IV, or Recurrent Non-Small Cell Lung Cancer
- Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)
Drugs in development (1)
- Fluticasone propionate Phase 2